Exenatide enhances cognitive performance and upregulates neurotrophic factor gene expression levels in diabetic mice

Fundamental and Clinical Pharmacology

Volumn 30, Issue 4, 2016, Pages 376-384

  Gumuslu, Esen ^a   Mutlu, Oguz ^a   Celikyurt, Ipek K ^a   Ulak, Guner ^a   Akar, Furuzan ^a   Erden, Faruk ^a   Ertan, Merve ^a  

^a KOCAELI UNIVERSITY   (Turkey)

Author keywords

BDNF; CREB; exenatide; memory; type 2 diabetes

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; EXENDIN 4; MESSENGER RNA; NEUROTROPHIC FACTOR; NICOTINAMIDE; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; ELEVATED PLUS MAZE TEST; GENE EXPRESSION; HIPPOCAMPUS; HYPERGLYCEMIA; LATENT PERIOD; LEARNING; LOCOMOTION; MEMORY; MEMORY CONSOLIDATION; MOOD; MOUSE; NEURITE; NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OPEN FIELD TEST; PASSIVE AVOIDANCE; PASSIVE AVOIDANCE TEST; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPATIAL MEMORY; SYNAPTIC TRANSMISSION;

EID: 84977517025     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/fcp.12192     Document Type: Article

References (59)

1. Hoyer S. Glucose metabolism and insulin receptor signal transduction in Alzheimer disease. Eur. J. Pharmacol. (2004) 490 115–125.
2. Gispen W.H., Biessels G.J. Cognition and synaptic plasticity in diabetes mellitus. Trends Neurosci. (2000) 23 542–549.
3. Biessels G.J., Kappelle L.J. Increased risk of Alzheimer's disease in Type II diabetes: insulin resistance of the brain or insulin-induced amyloid pathology? Biochem. Soc. Trans. (2005) 33 1041–1044.
4. Lebovitz H.E. Type 2 diabetes: an overview. Clin. Chem. (1999) 45 1339–1345.
5. Drab S.R. Incretin-based therapies for type 2 diabetes mellitus: current status and future prospects. Pharmacotherapy (2010) 30 609–624.
6. Kieffer T.J., Habener J.F. The glucagon-like peptides. Endocr. Rev. (1999) 20 876–913.
7. Gault V.A., Flatt P.R., O'Harte F.P. Glucose-dependent insulinotropic polypeptide analogues and their therapeutic potential for the treatment of obesity-diabetes. Biochem. Biophys. Res. Commun. (2003) 308 207–213.
8. Goke R., Fehmann H.C., Linn T. et al. Exendin-4 is a high potency agonist and truncated exendin- (9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J. Biol. Chem. (1993) 268 19650–19655.
9. Montrose-Rafizadeh C., Yang H., Rodgers B.D., Beday A., Pritchette L.A., Eng J. High potency antagonists of the pancreatic glucagon-like peptide-1 receptor. J. Biol. Chem. (1997) 272 21201–21206.
10. Gong N., Ma A., Zhang L.J. et al. Site-specific PEGylation of exenatide analogues markedly improved their glucoregulatory activity. Br. J. Pharmacol. (2011) 163 399–412.
11. Alvarez E., Martinez M.D., Roncero I. et al. The expression of GLP-1 receptor mRNA and protein allows the effect of GLP-1 on glucose metabolism in the human hypothalamus and brainstem. J. Neurochem. (2005) 92 798–806.
12. Sarkar S., Fekete C., Legradi G., Lechan R.M. Glucagon like peptide-1 (7-36) amide (GLP-1) nerve terminals densely innervate corticotropin-releasing hormone neurons in the hypothalamic paraventricular nucleus. Brain Res. (2003) 985 163–168.
13. Hamilton A., Holscher C. Receptors for the insulin-like peptide GLP-1 are expressed on neurons in the CNS. NeuroReport (2009) 20 1161–1166.
14. Chowen J.A., de Fonseca F.R., Alvarez E., Navarro M., García-Segura L.M., Blázquez E. Increased glucagon-like peptide-1 receptor expression in glia after mechanical lesion of the rat brain. Neuropeptides (1999) 33 212–215.
15. Biswas S.C., Buteau J., Greene L.A. Glucagon-like peptide-1 (GLP-1) diminishesneuronal degeneration and death caused by NGF deprivation by suppressing Bim induction. Neurochem. Res. (2008) 33 1845–1851.
16. During M.J., Cao L., Zuzga D.S. et al. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat. Med. (2003) 9 1173–1179.
17. Perry T., Lahiri D.K., Sambamurti K. et al. Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. J. Neurosci. Res. (2003) 72 603–612.
18. Qin Z., Sun Z., Huang J., Hu Y., Wu Z., Mei B. Mutated recombinant human glucagon-like peptide-1 protects SH-SY5Y cells from apoptosis induced by amyloid-beta peptide (1-42). Neurosci. Lett. (2008) 444 217–221.
19. Gault V.A., Hölscher C. GLP-1 agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid. Eur. J. Pharmacol. (2008) 587 112–117.
20. Abbas T., Faivre E., Holscher C. Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: interaction between type 2 diabetes and Alzheimer's disease. Behav. Brain Res. (2009) 205 265–271.
21. Kwon K.J., Lee E.J., Kim M.K. et al. Diabetes augments cognitive dysfunction in chronic cerebral hypoperfusion by increasing neuronal cell death: implication of cilostazol for diabetes mellitus-induced dementia. Neurobiol. Dis. (2015) 73 12–23.
22. Barco A., Pittenger C., Kandel E.R. CREB, memory enhancement and the treatment of memory disorders: promises, pitfalls and prospects. Expert. Opin. Ther. Targets (2013) 7 101–114.
23. Tomonori N., Tomoko T., Taeko O. et al. Establishment and pathophysiological characterization of type 2 diabetic mouse model produced by streptozotocin and nicotinamide. Biol. Pharm. Bull. (2006) 29 1167–1174.
24. Firdous M., Koneri R., Sarvaraidu C.H., Harish M., Shubhapriya K.H. NIDDM antidiabetic activity of saponins of momordica cymbalaria in streptozotocin-nicotinamide NIDDM mice. J Clin Diagn Res (2009) 3 1460–1465.
25. Chen T., Kagan L., Mager D.E. Population pharmacodynamic modeling of exenatide after 2-week treatment in STZ/NA diabetic rats. J. Pharm. Sci. (2013) 102 3844–3851.
26. Reddy D.S., Kulkarni S.K. Possible role of nitric oxide in the nootropic and antiamnesic effects of neurosteroids on aging- and dizocilpine-induced learning impairment. Brain Res. (1998) 799 215–229.
27. Hlinak Z., Krejci I. Oxiracetam prevents the MK-801 induced amnesia for the elevated plus-maze in mice. Behav. Brain Res. (2000) 117 147–151.
28. Ogren S.O. Evidence for a role of brain serotonergic neurotransmission in avoidance learning. Acta Physiol. Scand. Suppl. (1985) 544 1–71.
29. Phillips R.G., LeDoux J.E. Differential contribution of amygdala and hippocampus to cued and contextual fear conditioning. Behav. Neurosci. (1992) 106 274–285.
30. Belzung C. Measuring exploratory behavior, in: Crusio W.E., Gerlai R.T. (Eds), Handbook of molecular genetic techniques for brain and behavior research (Techniques in the Behavioral and Neural Sciences), Elsevier, Amsterdam, 1999, pp. 739–749.
31. Savlı H., Aalto Y., Nagy B., Knuutila S., Pakkala S. Gene expression analysis of 1,25(OH)2D3 dependent differentiation of HL-60 cells—a cDNA array study. Br. J. Haematol. (2002) 118 1065–1072.
32. Savlı H., Karadenizli A., Kolaylı F., Gundes S., Ozbek U., Vahaboglu H. Expression stability of six housekeeping genes: a proposal for resistance gene quantification studies of Pseudomonas aeruginosa by real-time quantitative RT-PCR. J. Med. Microbiol. (2003) 52 403–408.
33. Masiello P., Broca C., Gross R. et al. Experimental NIDDM: development of a new model in adult rats administered streptozotocin and nicotinamide. Diabetes (1998) 47 224–229.
34. Trudeau F., Gagnon S., Massicotte G. Hippocampal synaptic plasticity and glutamate receptor regulation: influences of diabetes mellitus. Eur. J. Pharmacol. (2004) 490 177–186.
35. Watson G.S., Craft S. Modulation of memory by insulin and glucose: neuropsychologial observations in Alzheimer's disease. Eur. J. Pharmacol. (2004) 490 97–113.
36. Strachan M.W. Insulin and cognitive function in humans: experimental data and therapeutic considerations. Biochem. Soc. Trans. (2005) 33 1037–1040.
37. Iwai T., Suzuki M., Kobayashi K., Mori K., Mogi Y., Oka J.I. The influences of juvenile diabetes on memory and hippocampal plasticity in rats: improving effects of glucagon-like peptide-1. Neurosci. Res. (2009) 64 67–74.
38. Baggio L.L., Drucker D.J. Biology of incretins: GLP-1 and GIP. Gastroenterology (2007) 132 2131–2157.
39. McClean P.L., Parthsarathy V., Faivre E., Holscher C. The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. J. Neurosci. (2011) 31 6587–6594.
40. Porter D.W., Kerr B.D., Flatt P.R., Holscher C., Gault V.A. Four weeks administration of Liraglutide improves memory and learning as well as glycaemic control in mice with high fat dietary-induced obesity and insulin resistance. Diabetes Obes. Metab. (2010) 12 891–899.
41. Gault V.A., Porter W.D., Flatt P.R., Holscher C. Actions of exendin-4 therapy on cognitive function and hippocampal synaptic plasticity in mice fed a high-fat diet. Int. J. Obes. (2010) 34 1341–1344.
42. Stranahan A.M., Norman E.D., Lee K. et al. Diet-induced insulin resistance impairs hippocampal synaptic plasticity and cognition in middle-aged rats. Hippocampus (2008) 18 1085–1088.
43. Isacson R., Nielsen E., Dannaeus K. et al. The glucagon-like peptide 1 receptor agonist exendin-4 improves reference memory performance and decreases immobility in the forced swim test. Eur. J. Pharmacol. (2011) 650 249–255.
44. Wang X.H., Li L., Holscher C., Pan Y.F., Chen X.R., Qi J.S. Val8-glucagon-like peptide-1 protects against Abeta1-40-induced impairment of hippocampal late-phase long-term potentiation and spatial learning in rats. Neuroscience (2010) 170 1239–1248.
45. Silva A.J., Kogan J.H., Frankland P.W., Kida S. CREB and memory. Annu. Rev. Neurosci. (1998) 21 127–148.
46. Kida S. A functional role for CREB as a positive regulator of memory formation and LTP. Exp. Neurobiol. (2012) 21 136–140.
47. McClean P.L., Gault V.A., Harriott P., Holscher C. Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer's disease. Eur. J. Pharmacol. (2010) 630 158–162.
48. Sheng M., Thompson M.A., Greenberg M.E. CREB: a Ca(+2)-regulated transcription factor phosphorylated by calmodulin-dependent kinase. Science (1991) 252 1427–1430.
49. Kawashima T., Okuno H., Nonaka M. et al. Synaptic activity-response element in the Arc/Arg3.1 prometer essential for synapse-to-nucleus signaling in activated neurons. Proc. Natl Acad. Sci. USA (2009) 106 316–321.
50. Finkbeiner S., Tavazoie S.F., Maloratsky A., Jacobs K.M., Harris K.M., Greenberg M.E. CREB: a major mediator of neural neutrophin responses. Neuron (1997) 19 1031–1047.
51. Tardito D., Perez J., Tiraboschi E., Musazzi L., Racagni G., Popoli M. Signaling pathways regulating gene expression, neuroplasticity, and neurotrophic mechanisms in the action of antidepressants: a critical overview. Pharmacol. Rev. (2006) 58 115–134.
52. Ernfors P., Ibáñez C.F., Ebendal T., Olson L., Persson H. Molecular cloning and neurotrophic activities of a protein with structural similarities to nerve growth factor: developmental and topographical expression in the brain. Proc. Natl. Acad. Sci. U S A. (1990) 87 5454–5458.
53. Scaccianoce S., Del Bianco P., Caricasole A., Nicoletti F., Catalani A. Relationship between learning, stress and hippocampal brain-derived neurotrophic factor. Neuroscience (2003) 121 825–828.
54. Lu B. BDNF and activity-dependent synaptic modulation. Learn. Mem. (2003) 10 86–98.
55. Mu J.S., Li W.P., Yao Z.B., Zhou X.F. Deprivation of endogenous brain-derived neurotrophic factor results in impairment of spatial learning and memory in adult rats. Brain Res. (1999) 835 259–265.
56. Aydemir C., Yalcin E.S., Aksaray S. et al. Brain-derived neurotrophic factor (BDNF) changes in the serum of depressed women. Prog. Neuropsychopharmacol. Biol. Psychiatry (2006) 30 1256–1260.
57. Barad M., Bourtchouladze R., Winder D.G., Golan H., Kandel E. Rolipram, a type IV specific phosphodiesterase inhibitor, facilitates the establishment of long-lasting long-term potentiation and improves memory. Proc. Natl Acad. Sci. USA (1998) 95 15020–15025.
58. Bliss T., Lømo T. Long-lasting potentiation of synaptic transmission in the dentate area of the anaesthesised rabbit following stimulation of the perforant path. J. Physiol. London (1973) 232 331–356.
59. Collingridge G.L., Bliss T.V.P. NMDA receptors—their role in long-term potentiation. Trends Neurosci. (1987) 10 288–293.